The pharmaceutical industry, one of the most crucial in the world in terms of impact on the lives of patients – from relieving pain to conquering disease – is in the midst of significant initiatives to improve transparency and build stronger public trust. To ensure ethical practice in the promotion of new therapies to healthcare professionals (HCPs), governments in the US and now in Europe have tightened regulations to ensure that companies foster a culture of compliance and transparency.
Francis Geysermans, co-founder at life sciences compliance software provider BMI SYSTEM, believes that these regulations represent a major shift that is just beginning to take hold in this industry. “Currently, just 25 per cent of companies have grasped the importance of this charge”.
For more information, read the full article.